Ionis Pharmaceuticals Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.67%.
Did IONS Beat Earnings? Q2 2025 Results
Ionis Pharmaceuticals delivered a blowout second quarter, posting earnings per share of $0.70 against a consensus estimate of just $0.16, a beat of 326.05%, while revenue doubled year-over-year by 100.7% to $452.00 million, clearing Wall Street's $299.00 million forecast by 51.18%. The single biggest driver was a $280.00 million upfront licensing payment from Ono Pharmaceutical for global rights to sapablursen, which pushed collaborative agreement revenue to $337.00 million and swung GAAP operating income to $140.00 million from a $66.00 million loss a year ago. Layered on top, TRYNGOLZA generated $19.00 million in net product sales in just its second full quarter on the market, while SPINRAZA royalties contributed $54.00 million to a 43% rise in commercial revenue. Shares climbed roughly 8% in pre-market trading following the report. Buoyed by the momentum, Ionis raised its full-year 2025 revenue guidance for the second time, now targeting $825.00 million to $850.00 million, with a potential FDA decision on donidalorsen for hereditary angioedema expected August 21, 2025, representing the company's next independent commercial launch.
- TRYNGOLZA net product sales of $19 million in Q2 2025 in its second full quarter on the market
- Revenue doubled year-over-year driven by TRYNGOLZA launch, increased royalties, and R&D revenues
- $280 million upfront payment from Ono Pharmaceutical for global license of sapablursen
- Commercial revenue increased 43% year-over-year to $103 million
- SPINRAZA global sales of $393 million generating $54 million in royalties
- WAINUA sales of $44 million generating $10 million in royalties, up from $4 million in Q2 2024
“During the second quarter, we continued to build momentum across our business. Our strong performance included excellent commercial execution, resulting in a substantial increase in TRYNGOLZA revenues, our first independently launched medicine. We expect additional advancements in the second half, including Ionis' second independent launch with donidalorsen for hereditary angioedema, anticipated next month, and important Phase 3 results for olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease. We believe these four programs collectively represent multi-billion-dollar revenue potential and a transformational opportunity for Ionis and for patients.”
Ionis Pharmaceuticals CEO, on the earnings call
Forward Guidance & Outlook
Ionis raised its full-year 2025 financial guidance for the second time, reflecting an improved outlook and strong year-to-date performance. New guidance calls for total revenue of $825-850 million (up from $725-750 million), TRYNGOLZA net product sales of $75-80 million (newly introduced), non-GAAP operating loss of $300-325 million (improved from <$375 million), and cash/cash equivalents/short-term investments of approximately $2.0 billion (up from ~$1.9 billion). The company anticipates three additional independent launches over the next eighteen months — donidalorsen for HAE (PDUFA August 21, 2025), olezarsen in sHTG, and zilganersen in Alexander disease — which management expects will drive substantial and growing product revenue. Coupled with increasing partner royalty revenue and disciplined investment, Ionis is positioned to achieve sustained growth and positive cash flow in the next few years.
IONS YoY Financials
IONS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.